The COAPT Risk Score¹ is a simple risk prediction tool created by combining clinical and echocardiographic variables in patients with heart failure (HF) and moderate-to-severe or severe functional mitral regurgitation (FMR) who remain symptomatic despite maximally tolerated guideline directed medical therapy (GDMT). The COAPT Risk Score provides valuable prognostic information regarding the 2-year risk of death and/or heart failure hospitalization (HFH). The score is derived from the COAPT trial² population of patients with HF and moderate-to-severe or severe FMR randomized to treatment with either transcatheter edge-to-edge repair (TEER) with MitraClip plus GDMT or GDMT alone. We can incorporate TEER in the risk score and provide updated 2-year risk of death and/or HFH which can serve as a valuable shared decision-making tool for patients and physicians as well as heart teams while deciding about TEER.

The COAPT Risk Score has been externally validated in several registries^3-5 showing fair predictive accuracy. Additionally, continued follow-up of COAPT trial patients showed that TEER was safe and effective with lower rate of death and HFH (compared to GDMT alone) at 3 years⁶ and 5 years.⁷

For full-text link to the COAPT risk score paper, please click here.